Quell Therapeutics Ltd

The shape of the political landscape that our sector will navigate this year became clear at the Labour Party conference in Liverpool last week. The new Labour government will unveil its industrial strategy, hold a Global Investment Summit, and meet with the Life Science Council before the key moment of the Budget on 30 October.

I’m delighted to finally be able to leave the house today after my period of isolation after a positive COVID-19 test. It was such a shame not to be able to join our bioprocessing community last week for the 18th annual bioProcess UK conference but I have been enjoying looking at the photos from this great event. News over the weekend of the Omnicron variant has led to the postponement of the WTO Ministerial meeting in Geneva where waivers on the IP of COVID-19 vaccines were to be discussed, so I’m no longer expecting to see global policy set in Geneva this week.

With a new Labour Government in place, this year’s event set the stage for impactful collaboration with MPs and policymakers. Read on to learn how we’re keeping life sciences at the top of the agenda.

Quell Therapeutics CEO, Iain McGill and the team welcomed Rt Hon Rachel Reeves, Chancellor of the Exchequer, to the Translation & Innovation Hub in London to officially open their newly refurbished offices.

Pension reform unlocks cash for UK life sciences, London Life Sciences Week and #bioProcessUK are here.

Quell Therapeutics expands manufacturing capabilities for CAR-Treg cell therapy pipeline through partnership with eXmoor pharma. The multi-year agreement focuses on the manufacture of multiple CAR-Treg product candidates for Phase 1/2 clinical studies.